Canada: Food, Drugs, Healthcare, Life Sciences

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

Les nouvelles lignes directrices du CEPMB sont enfin disponibles

Le 30 juin, le Conseil d'examen du prix des médicaments brevetés (le « CEPMB ») a publié les Lignes directrices pour le personnel du CEPMB...

Canada Healthcare

FF

Fasken (French)

Tory Hibbitt Co-authors Annotated Alberta Health Information Act

Tory Hibbitt co-authors a comprehensive text on Alberta's Health Information Act and how this important legislation is interpreted and applied.

Canada Healthcare

MT

Miller Thomson LLP

The Court Grants An Appeal In Favour Of Psychedelic Assisted Psychotherapy – Toth v. Canada, 2025 FCA 119

A ruling from the Federal Court of Canada has resulted in an appeal of prior government refusals to permit access to psilocybin in connection with psilocybin assisted psychotherapy ("PSAP").

Canada Healthcare

ML

McMillan LLP

Ontario Announces New Call For Applications To Deliver Community-Based Orthopedic Services

On July 2, 2025, the Director of Integrated Community Health Services Centres (the "Director") issued a call for applications for new integrated community health services centre...

Canada Healthcare

F

Fasken

Complaint Underscores Risks Of Billing Outside OHIP: Physicians Take Note

Canada Healthcare

RS

Rosen Sunshine LLP

2025 Mid-year Highlights In Canadian Life Sciences IP And Regulatory Law

Canada Healthcare

SB

Smart & Biggar

More Convenient Care Act, 2025: New Obligations To Come For Health Care Facility Staffing Agencies

Canada Healthcare

BL

Borden Ladner Gervais LLP

Applications To License Community Surgical And Diagnostic Centres For Orthopedic Services Now Underway

Canada Healthcare

RS

Rosen Sunshine LLP

At Long Last: The New PMPRB Guidelines Are Here

Worldwide Healthcare

F

Fasken

CDA Opens Consultation On Proposed List Of Drugs To Inform Development Of National Formulary

Canada Healthcare

SB

Smart & Biggar

Closing The Value Gap Using Earnouts In Life Sciences M&A

Canada Healthcare

AB

Aird & Berlis LLP

North Of Legal Or South Of Safe? Key Legal And Regulatory Considerations To Substantiate "Made In Canada" Claims

Canada Healthcare

LS

Lenczner Slaght LLP

CDA Opens Public Consultation On Pharmacare National Formulary – Deadline July 18, 2025

Canada Healthcare

F

Fasken

Health Canada's New Draft Guidance For Biosimilar Biologic Drugs

Canada Healthcare

F

Fasken

Using COVID-19 Benefits Fraudulently Will Get You Charged With Tax Evasion By The CRA

RS

Rotfleisch & Samulovitch P.C.

How CRA Conducts Net Worth Audits And Enforces Gross Negligence Penalties Against Canadian Taxpayers: Lessons From Mann v. The King And Other Cases

RS

Rotfleisch & Samulovitch P.C.

Timing Isn't Everything: Termination Upon Return From A Protected Leave Of Absence

Canada Employment

F

Fasken

Canadian Intellectual Property Office "Next Generation Patents" Update And Status As Of May 13, 2025

SB

Smart & Biggar

Wagg Motions: Reforms Needed To Stop Delays And Unnecessary Costs When Accessing Criminal Records For Civil Sexual Assault Proceedings

Canada Litigation

LL

Lerners LLP

See more

Food and Drugs Law

Insights From Health Canada's 2024–2025 Statistical Report On Canadian Pharmaceutical Patent Regime

On July 25, 2025, Health Canada released its annual 2024–2025 Statistical Report for the Patented Medicines (Notice of Compliance) Regulations, Data Protection...

MT

McCarthy Tétrault LLP

Patented Medicine Prices Review Board Publishes New Guidelines For PMPRB Staff: Finally, Some Guidance For Patentees

On June 30, the Patented Medicine Prices Review Board (PMPRB) published new Guidelines for PMPRB Staff (the Guidelines) that will take effect on Jan. 1, 2026.

BL

Borden Ladner Gervais LLP

Les nouvelles lignes directrices du CEPMB sont enfin disponibles

Le 30 juin, le Conseil d'examen du prix des médicaments brevetés (le « CEPMB ») a publié les Lignes directrices pour le personnel du CEPMB...

Canada Healthcare

FF

Fasken (French)

The Court Grants An Appeal In Favour Of Psychedelic Assisted Psychotherapy – Toth v. Canada, 2025 FCA 119

Canada Healthcare

ML

McMillan LLP

Patents And Prior Art: Federal Court Clarifies Standards For Anticipation And Obviousness

AB

Aird & Berlis LLP

2025 Mid-year Highlights In Canadian Life Sciences IP And Regulatory Law

Canada Healthcare

SB

Smart & Biggar

Important New Procedural Guidelines From The PMPRB

AM

Aird & McBurney LP

Final Guidelines From Canada's PMPRB: The New Era Begins

TL

Torys LLP

The Trademark Four(Mula): Enforcement And Risk Mitigation

OH

Osler, Hoskin & Harcourt LLP

See more

Life Sciences, Biotechnology & Nanotechnology

Patented Medicine Prices Review Board Publishes New Guidelines For PMPRB Staff: Finally, Some Guidance For Patentees

On June 30, the Patented Medicine Prices Review Board (PMPRB) published new Guidelines for PMPRB Staff (the Guidelines) that will take effect on Jan. 1, 2026.

BL

Borden Ladner Gervais LLP

Les nouvelles lignes directrices du CEPMB sont enfin disponibles

Le 30 juin, le Conseil d'examen du prix des médicaments brevetés (le « CEPMB ») a publié les Lignes directrices pour le personnel du CEPMB...

Canada Healthcare

FF

Fasken (French)

The Court Grants An Appeal In Favour Of Psychedelic Assisted Psychotherapy – Toth v. Canada, 2025 FCA 119

A ruling from the Federal Court of Canada has resulted in an appeal of prior government refusals to permit access to psilocybin in connection with psilocybin assisted psychotherapy ("PSAP").

Canada Healthcare

ML

McMillan LLP

2025 Mid-year Highlights In Canadian Life Sciences IP And Regulatory Law

Canada Healthcare

SB

Smart & Biggar

Important New Procedural Guidelines From The PMPRB

AM

Aird & McBurney LP

Final Guidelines From Canada's PMPRB: The New Era Begins

TL

Torys LLP

Finalized PMPRB Guidelines Published

SB

Smart & Biggar

At Long Last: The New PMPRB Guidelines Are Here

Worldwide Healthcare

F

Fasken

CDA Opens Consultation On Proposed List Of Drugs To Inform Development Of National Formulary

Canada Healthcare

SB

Smart & Biggar

See more

Healthcare

From Lab To App: NiaHealth Raises C$5.75M To Redefine Canadian Health Monitoring

The Alberta-based startup NiaHealth has secured C$5.75 million in seed funding to support its mission of transforming long-term health management for Canadians.

Canada Technology

GL

Goodmans LLP

Legislative Update Report No. 2025-14 Le Bulletin D'actualités Législatives

Osler's Legislative Update is a bi-weekly listing of new legislation. This issue covers legislation for the period 07/10 to 07/23...

Canada Government

OH

Osler, Hoskin & Harcourt LLP

Insights From Health Canada's 2024–2025 Statistical Report On Canadian Pharmaceutical Patent Regime

On July 25, 2025, Health Canada released its annual 2024–2025 Statistical Report for the Patented Medicines (Notice of Compliance) Regulations, Data Protection...

MT

McCarthy Tétrault LLP

Tory Hibbitt Co-authors Annotated Alberta Health Information Act

Canada Healthcare

MT

Miller Thomson LLP

The Court Grants An Appeal In Favour Of Psychedelic Assisted Psychotherapy – Toth v. Canada, 2025 FCA 119

Canada Healthcare

ML

McMillan LLP

Ontario Announces New Call For Applications To Deliver Community-Based Orthopedic Services

Canada Healthcare

F

Fasken

Complaint Underscores Risks Of Billing Outside OHIP: Physicians Take Note

Canada Healthcare

RS

Rosen Sunshine LLP

2025 Mid-year Highlights In Canadian Life Sciences IP And Regulatory Law

Canada Healthcare

SB

Smart & Biggar

Ontario : Nouveau guide de gestion de la protection de la vie privée à l'intention des petits organismes de soins de santé

BC

Blake, Cassels & Graydon LLP

See more

Patents

Genentech And U Penn Settle HERCEPTIN Patent Suit

On June 8, 2012, Genentech’s lawsuit seeking a declaration that US Patent No. 6,733,752 was invalid and not-infringed by Genentech’s trastuzumab product (HERCEPTIN).

BR

Beeser Ramamoorthy LLP

Subsequent-Entry Biologic Patent Litigation Commences In Canada

Health Canada specifically contemplates certain proteins as SEBs in its Guidance, although Health Canada has not limited SEBs to only particular classes of drugs.

SB

Smart & Biggar

Pharma In Brief - Canada: Federal Court Reduces Claim For Section 8 Damages Based On Defence Of Ex Turpi Causa [MEVACOR® (lovastatin)]

On May 23, 2012, the Federal Court held that Merck Frosst Canada Ltd. ("Merck") is liable to Apotex Inc. ("Apotex") for damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (the "Regulations"), but exercised its discretion to reduce the amount of compensation payable based on a defence of ex turpi causa.

Canada Healthcare

NR

Norton Rose Fulbright Canada LLP

U.S. Appeals Court Overturns District Court's Finding Of Obviousness (AMRIX/Cyclobenzaprine Hydrochloride)

BR

Beeser Ramamoorthy LLP

Consultation On PMPRB Guidelines

Canada Healthcare

BL

Borden Ladner Gervais LLP

Drug Pricing & Reimbursement @ Gowlings: May 1, 2012 - Volume 6, Number 2

Canada Healthcare

GW

Gowling WLG

Patent Refused Listing On The Patent Register (Intellectual Property Weekly Abstracts, Week Of April 30, 2012)

BL

Borden Ladner Gervais LLP

Extending Recent Promised Utility Doctrine Beyond Pharmaceutical And Chemical Cases

GW

Gowling WLG

Pharmacapsules @ Gowlings: April 11, 2012 - Volume 11, Number 5

Canada Healthcare

GW

Gowling WLG

See more

Latest Videos

See more

Bothwell V. London Health Sciences Centre, 2023 ONCA 323; Mental Health Injury Update (Video)

SB

SBA Lawyers LLP

Medical Malpractice Future Trends With Charles E. Gluckstein (Video)

GP

Gluckstein Lawyers

What's Next For Ontario's Public Health Care? (Video)

F

Fasken

The Legal Steps To Startups: Health & Life Science (Video)

PM

Parlee McLaws

How To Protect Ideas In The Booming Life Sciences Sector (Video)

GW

Gowling WLG

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More